Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
205.00
+1.68 (+0.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
Next >
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 30, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
May 29, 2024
From
Schall Law
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
May 28, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB
May 28, 2024
From
Robbins LLP
Via
Business Wire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
May 28, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
May 24, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
May 24, 2024
From
Robbins LLP
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
May 24, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
May 23, 2024
From
Kirby McInerney LLP
Via
Business Wire
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 23, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
May 23, 2024
From
Schall Law
Via
GlobeNewswire
BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 23, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
From
Biogen Inc.
Via
GlobeNewswire
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Reports Progress on Corporate Responsibility Priorities
May 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Via
MarketBeat
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
March 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
February 24, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 23, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From
Biogen Inc.
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 22, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 21, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From
Biogen Inc.
Via
GlobeNewswire
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.